top of page
Licensing Partnerships
Evaluating licensing partnership potential in the rare and infectious disease market
Collaborations Pharmaceuticals, Inc. (CPI), founded in 2016, specializes in therapeutics research and development for various rare and neglected infectious diseases. They supplement their drug discovery process with intelligence (AI) software and machine learning models developed in-house, and offer similar services to other pharmaceutical and consumer companies. Through this project, the MMB team aims to support CPI in identifying and securing external partners who have the financial capacity and knowledge to license assets in CPI’s pipeline, and research market potential for CPI’s drug candidates.
bottom of page